Coronavirus: Medical Treatments

Department of Health and Social Care written question – answered at on 7 February 2023.

Alert me about debates like this

Photo of Lord Mendelsohn Lord Mendelsohn Labour

To ask His Majesty's Government, further to the creation by NHS England of a national expert working group (EWG), why it has only met twice; and whether it still has an active role in supporting the development of a national clinical policy.

Photo of Lord Markham Lord Markham The Parliamentary Under-Secretary for Health and Social Care

As part of pandemic-specific arrangements, NHS England was asked to utilise its national clinical policy making expertise to lead on the development of United Kingdom-wide clinical access policy drafts enabling access to evidence-based COVID treatments. These draft policies are then considered and approved by the UK Chief Medical Officers ahead of publication, to guide the decisions of treating clinicians, and supporting medicines supply arrangements.

NHS England has been supported in this role by a range of clinical and academic experts, including representatives from the devolved administrations in Northern Ireland, Scotland and Wales, who meet as part of Expert Working Group arrangements. There is not a standing or single expert working group but rather a series of clinical policy-specific expert working groups that have been established and that meet, as required, with clinical expertise specific to the medicine or medicines being considered. For example, an expert working group was established specific to Evusheld as pre-exposure prophylaxis, which met twice.

Through this expert working group approach, clinicians and academics have provided advice which has helped clinical policy makers to better understand the supporting clinical trial information, to identify any important contraindications or drug to drug interactions that need to be considered, and to understand how best to place a potential new medicine option alongside current treatment choices. This has provided NHS England with both clinical subject matter and specialty expertise and a valuable ‘front line’ perspective in developing access policy proposals.

Does this answer the above question?

Yes0 people think so

No9 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.